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ABSTRACT

MICROFLUIDIC CELL SORTING TECHNIQUES TO STUDY DISEASE PROCESSES

William Neil White
August 6, 2009

Circulating nucleated cell populations found in whole blood, including both white blood cells
(leukocytes) and endothelial cells, provide an ideal platform for studies seeking to understand
the disease processes for development of drugs and treatments. This thesis presents an
automated microfluidic device developed for leukocyte enrichment from peripheral blood.
Briefly, the device allows for complete lysis of red blood cells and comprehensive analysis of
nucleated cell populations in terms of quantity and activation status. The microfluidic lysis
device was used in two Sickle Cell disease (SCD) studies to understand the eftect of
leukocytes in the initiation of vasoocclusivc crisis. Findings suggest abnormally high
baseline leukocyte counts and variance in clinical expression among SCD patients. Hence, a
highly favorable state for an inflammatory reaction that may lead to vasoocclusive episodes
exists. To ascertain risk factors in such incidents revision of current SeD patient
classification is needed.
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CHAPTER I - INTRODUCTION

1.1 MICROFLUIDICS

Microfluidics has been defined by George M. Whitesides [I] as the SCIence and
technology of systems that process or manipulate small (10- 9 to 10-8 liters) amounts of
fluids, using channels with dimensions of tens to hundreds of micrometers. Emergence of
this distinct field was inspired by four disciplines: molecular analysis, biodefense,
molecular biology and microelectronics. With origins in analysis, success with
transforming analytical methods such as gas-phase chromatography and capillary
electrophoresis to the microscale by capillary format influenced other applications of
microfluidics. A primary stimulus for sudden growth of the micro fluidic field came in the
1990s with the US Department of Defense developing small-scale systems to detect
chemical and biological threats. Molecular biology acted as a third motivational source
with the wave of genomics because of the need for high-throughput analysis with greater
sensitivity and resolution. Application of fabrication techniques such as photolithography
from

silicon

microelectronics

and

microelectromechanical

systems

(MEMS),

nonetheless, has been the most essential for the development of micro fluidic
technologies. Because of the material restraints of silicon, steel and glass with biological
samples due to gas permeability, these fabrication techniques were not directly applicable
at first; although, such materials are now used to build specialized system that require
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thermal or magnetic support. Hence, an optically transparent, soft and biologicallyfriendly elastomer known as poly(dimethylsiloxane), or PDMS, was developed.

Properties of PDMS make it a suitable platform for miniaturized biological studies. Soft
lithographic techniques are used to fabricate PDMS devices that are capable of
controlling fluid flow in molded microchannels for a variety of purposes: immunoassays,
separation of proteins and DNA, formation of molecular gradients and sorting of cells.
Common methods for sorting or enriching cell populations on the micro scale include
magnetic filtration, fluorescent activated cell sorter (F ACS), hydrodynamics and inertial
focusing [2]. The PDMS microfluidic lysis device described in this thesis is a nucleated
cell enrichment device that takes advantage of the ability to manipulate cells in a
microfluidic system to expose whole blood to hypotonic conditions for a controlled
amount of time in a constant environment.

1.2 SCALING EFFECTS

Although the study of fluid mechanics is an old discipline, interest has only moved
toward fluids on a smaller scale in the past decades. In this realm fluids behavior is
significantly different as the forces that act on the macroscale become negligent on the
micro scale and vice versa, phenomena due to scaling effects. The concept of scaling
expresses variation of physical quantities of a given object or system with respect to size,
while keeping other quantities (time, pressure, temperature) constant. Applying this to
dimensionless parameters that convey the quality of tluid flow reveals the dominating
physical quantities of the microscale. Dimensionless fluidic numbers include Reynolds
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(inertia -:-- viscosity), Knudsen (molecular spacing -:-- length scale), Peclet (convection -:-diffusion) and Weber (inertia -:-- surface force); indicating laminar flow (low Reynolds
number) and domination by molecules, diffusion over convection, and surface forces
over volume effects as the dimensions get smaller [3]. Harnessing these forces allows
design of unique devices for research or technical use.

1.3 THE MICROFLUIDIC ADV ANT AGE

Interest in the field of micro fluidics has become so large because of the umque
advantages that working on such a small scale provides. Apparent reasons for
miniaturization are small device size and minute sample or reagent volumes. Shrinking
the size of a device enables or enhances characteristics, portability and placement in
constrained areas, as well as the ability for mass fabrication. Use of small amounts of
reagents reduces assay costs and extends limited samples. Microfluidic technologies also
allow for the control of precise geometry of microstructures and constrained geometries
to confine molecules or mechanical forces, by means of microfabrication. Less obvious
benefits of miniaturization include increase in the ratio of surface area relative to volume
and high throughput devices operating through parallel arrays. High-aspect ratio and
increased throughput lead to more rapid and sensitive analysis.

1.3.1

CONVENTIONAL ENRICHMENT TECHNIQUES

Interrogating the immune status of an individual in terms of circulating nucleated cells
generates important information on condition of health and may help to diagnose disease.
Accessing these nucleated cell populations through blood sample collection is easier and
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more convenient than human expressIOn analyses involving tumor tissues. Contained
within these nucleated cells is essential genetic (DNA) and gene expression (RNA and
protein) data. Phenotype or activation molecules expressed on the cell membrane also
bear significance. To examine these nucleated cells in circulation, such as white blood
cells (leukocytes), one must be able to enrich or sort the populations from other blood
components, including red blood cells (erythrocytes), and then isolate nucleic acids from
the cells of interest. Eliminating erythrocytes, which contain little genetic information, is
relevant as whole blood is composed of 45 % red blood cells, whereas leukocytes only
make up 1 %.

Ideally, sample prcparation in terms of sorting or enrichment takes advantage of certain
cell properties. Conventional techniques sort blood leukocytes by impedance using flow
cytometry and enrich cells by density and osmotic properties using Ficol density gradient
separation and ammonium chloride lysis. However, maintaining a constant environment
for all cells and controlling exposure time to harsh conditions with these techniques is not
plausible. Because of the lack of sensitivity, cells and even certain populations are lost.
Furthermore, conventional techniques activate the cells and alter the cellular phenotype,
resulting in artifactual gene expression [4-6]. Hence, it is often impossible to directly
compare gene expression data obtained with conventional sample preparation techniques.
Additionally, protocols for conventional sample preparation techniques also vary
extensively between laboratories, another source of degradation in the value of the gene
expression data.
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Microarray technologies, employed to analyze gene expression data, are powerful and
widely-used tools for the simultaneous measurement of mRNA abundance of thousands
of genes. Despite considerable development, widespread use has been limited in clinical
medicine due to analytical complexities. In a recent report, Irizarray et al [7]
demonstrated significant variance in microarray analyses from different laboratories
using the same analytical platforms. The variance could be minimized and consistent
results obtained if the 'laboratory effect', or protocol variability, was eliminated. Weis et
al [8] also examined sources of error and variance in gene expression data from different
laboratories and platforms, and found that results were comparable when common
platforms and procedures were employed. Such reports stress the need for uniformity in
protocols and reduction of analytical variance by appropriate standardization.

1.3.2

ADDRESSING FLAWS IN CONVENTIONAL TECHNIQUES

Comparative functional genomics using high throughput microarrays provides an
unbiased platform for genome-wide transcriptome analysis to identify differences in gene
expression between a control group and well-defined patient populations. Blood
leukocytes provide an ideal sample for such studies. Enrichment of leukocytes from
blood without loss or artifactual activation is critical to gene expression profiling.
Currently leukocyte enrichment protocols are not automated, involve several usermediated steps and are associated with cell loss and artifactual Rctivation. Hence arises
the importance of sample preparation. The micro fluidic protocol introduced in this thesis
addresses the flaws associated with conventional leukocyte enrichment techniques and
exhibits relevance to clinical use through studies with Sickle cell disease (SeD) patients.

5

1.4 OUTLINE OF THESIS
Microfluidics continues to revolutionize the medical field with developments that are
able to encompass an entire bioichemical laboratory on the surface of a polymer based or
silicon chip. This thesis reports the use of microfluidics for applications in the biomedical
field. In particular, this paper addresses the variance among conventional enrichment
techniques affecting gene expression data and introduces an automated microfluidic
platform for clinical studies of disease processes.

Chapter two illustrates the microfluidic lysis device. The chapter begins with the theory
behind the device and the mechanism of cell lysis. Subsequent sections of the chapter
describe the microfabrication of the silicon master mold of the device and how the device
is prepared from a polymer using soft lithographic techniques. A thorough protocol for
running the microfluidic device and the unknown cell populations recovered using this
procedure wrap up the chapter.

Chapter three discusses aspects of Sickle cell disease (SCD), the disease process
examined in this thesis. The classical view of SCD, focusing on the genetics of red blood
cells (RBCs), is introduced, along with new studies looking at white blood cells (WBCs)
in the pathogenesis of SCD, the onset of a vasoocclusive crisis in the case of this
disorder. Functions of both RBCs and WBCs in the body are also presented, along with
descriptions of phenotype and activation markers used to investigate SCD. Section three
of this chapter states the difference between the populations analyzed in the two studies
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(Chapters 4 and 5) in this thesis and explores current treatments offered to patients in
cnsls.

Chapter four describes the first study of the thesis analyzing conventional techniques and
the microfluidic lysis protocol using healthy controls and mild phenotype SCD patients.
After an initial comparison of the conventional and micro fluidic protocols, a
comprehensive study between healthy controls and mild phenotype SCD patients
utilizing only the micro fluidic device is presented. Methods, materials, results and a brief
discussion are included, along with an introduction and motivation for the study.

Chapter five explains the second study of the thesis seeking to compare mild phenotype
versus symptomatic SCD patients. In this analysis only microtluidics is used to acquire
data. Layout of the chapter is similar to that of chapter 4.

Chapters six and seven provide the conclusions drawn from this thesis study and possible
future directions for further examinations.
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CHAPTER II - THE MICROFLUIDIC LYSIS DEVICE

2.1 THEORY AND MECHANISM

An automated microfluidic lysis protocol has been developed to accomplish enrichment
of leukocytes and other circulating nucleated cells without loss or artifactual activation.
The device (Figure 1) allows for whole blood to rapidly mix with deionized water for
10 seconds in a 50

~m

x 150

~m

~

cross-section microfluidic channel of length 128 cm.

Inlet: Deionize

water

Inlet: 2X Phoephate
buffered •• line

3.5 em

Figure 1. Detailed schematic of microfluidics lysis device.

Whole blood and deionized water are simultaneously introduced into the device via their
respective inlets to achieve a 1:30 blood-to-deionized water ratio, which produces
8

complete erythrocyte lysis within lOs. Flow rates of each solution (section 2.4) and total
volume determine cell exposure time. Due to a low Reynolds number laminar flow exists
in the microchannels, with diffusion acting as the dominating mixing force. Diffusion of
deionized water occurs on this level rather quickly, but cells take longer to spread evenly
throughout the channel and reach an equilibrium condition. Hence, double herringbone
structures on the bottom of the channel (Figure 2) ensure chaotic mixing and that all cells
are exposed to the same hypotonic conditions within the device. Characterized by
Stroock et al [9], the herringbone structures lie in a staggered formation on the bottom of
the channel and generate several pairs of counterrotating helical flows, which break up
and mix at each transition between groove patterns. Due to a high surface-area-to-volume
ratio these helical flows form rapidly in the channels as flowing particles make more
contact with the channel walls after rising upon contact with the grooves. Cells exposed
to hypotonic conditions in the channel allow water to cross the plasma membrane through
osmosis and eventually lyse due to hydrostatic pressure. Due to the comparative small
size, red blood cells lyse first, whereas more robust white blood cells withstand such
conditions longer. With a short, controlled exposure time to hypotonic conditions,
unwanted cell populations can be removed. After exposure to harsh conditions unlysed
cells are returned to isotonic conditions at the exit of the device and fixed using 2%
paraformaldehyde. The samples and reagents are automatically metered out in precise
predetermined volumes, and the constant flow conditions prevent sedimentation or cell
loss in the micro-channels. Complete and rapid mixing of the cells with the lysis buffer
streams were visually confirmed by microscopy (Figure 2).
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Inlet:
Whole Blood

Outlet:
Leukocytes

t

Double Herri ngbone Structure

eionized
Water

• 2XPBS

r

-

2XPBS

i

"" J

Erythrocyte
depleted
blOOd

Figure 2. Microscope images of the device at the inlet, herringbone structures in the
serpentine channels and outlet.

2.2 MICROFABRICATION
A silicon mold of the microfluidic device was fabricated usmg photolithographic
techniques with the equipment in the University of Louisville c\eanroom. To create
negative replicas of the channels, AutoCAD (Autodesk, Inc. , San Rafael, CA) was used
to generate a transparency mask (Fineline Imaging, Colorado Springs, CO). The silicon
wafer was treated with oxygen plasma in an asher (March Instruments, Concord, MA) for
five minutes (100 mTorr pressure, 100 mV power, 10 % O 2 concentration) and spin
coated with negative photoresist SU-8 (MicroChem, Newton, MA). After a soft exposure
bake (SEB) the silicon wafer was exposed to UV light using the AB-M mask aligner
(ABM, Inc., Scotts Valley, CA) followed by a post exposure bake (PEB). Finally the
silicon wafer was developed in BTS-220 (VWR International, LLC) to rid of uncrosslinked photoresist and flood exposed to UV light for 60 seconds. These processes were
performed twice as the microfluidic lysis device is a two layer device: channels and
ridges. SU-8 100 and SU-8 50 were used to create channels and ridges of heights 25 11m
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and 150

~m.

Parameters for SU-8 100/50 to obtain these channel heights are: Spread

500/500 RPM (ramp 10011 00), Spin 2000/4000 RPM for 15 seconds (ramp 50011 000),
SEB 70/20 minutes at 115 C, Expose 61/17 seconds, PEB 13/5 minutes at 115 C,
Develop 15/5 minutes. To determine correct spin and spread speeds, baking times, UV
exposure (based upon wavelength absorbance and exposure energy to film thickness) and
developing times, guidelines were generally followed from the MicroChem data sheets
on SU-8 50-100 (http://www.microchem.com/products/pdf/SU8_50-100.pdf).

The micro fluidics device was fabricated usmg soft lithographic techniques. The
elastomer poly(dimethylsiloxane) (PDMS; Dow Coming, Midland, MI) was mixed 10:1
with a cross-linker, poured on top the silicon wafer, and cured at 60 C for 12 h. The
elastomer with the replicated channels was released, and channel access holes were
punched with a 22-gauge needle. The PDMS wafer was irreversibly bonded to a glass
slide via oxygen plasma (100 mTorr pressure, 100 mV power, 10 % O2 concentration) for
one minute. Access tubing (Tygon; Miami Lakes, Fl) of slightly larger diameter was
press-fitted into the holes. Macro to micro interface is provided through a IS-gauge
syring needle tip (Microparts Inc., Eagan, MN), attached to the tubing on each of the
inlets.

2.3 PROTOCOL FOR RUNNING LYSIS DEVICE
After the microfluidic device has been fabricated and tested, experiments with
erythrocyte lysis are ready to begin. The following section details the modified protocol
for the microfluidic device.
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2.3.1
•

SAMPLE COLLECTION
Collect 4 milliliters of blood sample from median cubital vein, on the anterior
forearm vein of patient with heparin as anticoagulant in two 2 ml green top
vaccutainers.

•

Discard first 2 ml tube as it contains dislodged mature endothelial cells (false
positives).

•

Resuspend the second tube to mix heparin with blood; save immediately on ice.

•

Process the blood sample immediately (within one hour of collection).

2.3.2
•

PRIME MICROFLUIDIC DEVICE WITH PBS
Fill a I ml syringe with IX PBS and make sure to get rid of bubbles. Connect the
PBS-loaded 1 ml syringe to inlet 1 (Figure 3) on the microfluidic device. Push
the syringe containing the IX PBS gently by hand until the solution flows out of
inlet 2, and then immediately clamp inlet 2 with a standard office binder clip

•

Continue pushing the 1X PBS until fluid reaches the outlet port of the
microfluidics device. Once the solution flows out of the outlet, clamp the outlet
tubing with another binder clip.

•

Continue pushing the I ml syringe until the IX PBS flows out of inlet 3, and
clamp the inlet 3 port with another office binder clip. The microfluidics device is
now fully primed.

12

Inle! 1
(1X PBS/Sample)

Inlet 2
(Deionized water)

Figure 3. Schematic of device showing inlets for respective solutions and outlet.

2.3.3
•

PREPARATION OF SYRINGE PUMPS AND SOLUTION
To calibrate the pumps follow these steps:
o

For the large Harvard syringe pump (Harvard, PHD 22/2000 Part #
702001): Set the diameter configuration to 22.5 mm, flow rate 600 flllmin.

o

For the small Harvard Syringe pump (Harvard, PHD 22/2000 Part #
702209): Set the diameter configuration to 4.61 mm, flow rate 20 flllmin.

•

Fill one 30 ml syringe with sterile deionized water. This can be accomplished by
withdrawing the solution directly from the 50 ml conical tube. (Label the syringe)

•

Fill a second 30 ml syringe with 2X phosphate-buffered-saline (PBS), 2%
paraformaldehyde (PF A) using the procedure outlined in step 9. (Label the
syringe)

•

Fill a 1 ml syringe with IX PBS from the aliquots stored in the 4 ml Falcon tubes,
using the procedure outlined in step 9.

•

Remove the clamps and connect the 30 ml deionized water syringe to inlet 2 and
the 30 ml 2X PBS syringe to inlet 3 (make sure you don't trap bubbles in the
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tubing or microfluidics device). Remove the clamp from the outlet tubing.
Connect the lX PBS 1 ml syringe into inlet 1.

2.3.4
•

ERYTHROCYTE LYSIS
Set all of the syringes on the proper Harvard pumps as outlined below:
o

Set the two 30 ml syringes (one containing sterile, de-ionized water and
the other with 2X PBS, 2% PF A) together on the large Harvard syringe
pump.

o

Set the 1 ml syringe (containing lX PBS) on the small Harvard syringe
pump.

o

Place the outlet tubing in a waste collector (50 ml conical tube that is
labeled "waste").

•

Tum on the large Harvard syringe pump (with the 30 ml syringes) and let it run
for one minute. (Make sure there is no leakage in the device or in the tubing).

•

Tum on the small Harvard syringe pump and let it run for an additional mmute.
(Make sure there is no leakage in the device or in the tubing). Stop the pumps.
The microfluidics device is now ready to be used.

•

Remove the 1 mI syringe containing IX PBS from the small Harvard syringe
pump.

•

After obtaining a blood sample, fill the 1 mI syringe with 0.05 ml of sterile IX
PBS without trapping any bubbles. Next, fill the syringe with 0.5 mls of blood
obtained from the Eppendorf tube. (The 1 ml syringe will now contain a final
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volume of 0.55 mls of the blood and IX PBS buffer.) Note: Keep the syringe
vertical while filling to avoid mixing of the 0.05 ml PBS with the blood.
•

Connect the syringe containing the blood to inlet 1 and mount the synnge
carefully (avoid pushing the blood through the tubing into the device) on the
small Harvard syringe pump (the syringe is mounted vertical into the pump).

• Remove the outlet tubing from the "waste" tube and put a clean 50 ml centrifuge
tube in its place and set it on a bucket of ice.
•

Switch on the large Harvard syringe pump first and let it run for I minute. Start
c?llecting the_ sample from the outlet into the 50 ml centrifuge tube

•

Switch on the small Harvard syringe pump.

•

Once the blood sample in the 1 ml syringe has completely traveled through the
device, stop both pumps. This should take approximately 20 minutes.

• Centrifuge the collected sample for 5 minutes at 350 x g at room temperature with
the brake off.

•

Remove supernatant by placing pipette tip at the opposite side of the white pellet.
Remove as much supernatant as possible, especially red cell debris, without
disturbing the white pellet.

• Resuspend the sample in 1 ml of flow buffer.
• For sample analysis using flow cytometry, add 100 l.d of sample to a flow
cytometry tube.

• To the 100 f.!l of sample add specified antibody.
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•

Allow sample to incubate for 30 minutes at 40 C. Wash twice with flow buffer
prior to flow cytometry (add 250 JlI of flow buffer, vortex, spin at 350 g for 5
minutes, resuspend in 250 JlI of flow buffer).

2.4 ENABLING ANALYSIS OF UNKNOWN POPULATIONS

Upon analysis of enriched nucleated cells it is clear that the microfluidic lysis device
recovers populations of cells lost in conventional techniques (Figure 4a). Figure 4 shows
flow cytometry scatter plots of nucleated cell populations enriched by different
techniques grouped into regions by forward scatter (FSC) and side scatter (SSC) light,
sorting cells based upon size and granulation. Smaller and least granulated cells that fall
in Region 1 (red) are Lymphocytes. Region 2 (green) consists of larger and semigranulated Monocytes. Granulocytes, making up Region 3 (blue), are medium-sized and
highly-granulated cells. These three regions are the nucleated cells known as leukocytes
(refer to Section 3.2.2). Cells of interest include those in Region 4 (purple). These
nucleated populations not salvaged in the conventional techniques Ficol and NH4 CL lysis
(Figure 4b and 4c) are yet to be fully characterized. Preliminary evaluation has revealed
that this population of unknown cells stains for several antibodies (CD31, CD34, CD36,
CD61, VEGF R2, CD133, CD138, and CDI46), indicating the presence of multiple cell
types, including but not limited to progenitor endothelial, mature endothelial, myelocytes,
reticulocytes, megakaryocytes and other progenitor cells. Note that this may alter the
population ratio to total nucleated cells that has been determined by conventional
techniques. However, studies with the microfluidic device include controls to provide
baseline ratios.
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(a)

(b)

(c)

Figure 4. Comparison of unknown cell populations with different enrichment protocols.
Region 1 (red) represents Lymphocytes, Region 2 (green) includes Monocytes, Region 3
(blue) consists of Granulocytes, and Region 4 (purple) contains populations not yet fully
characterized.
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CHAPTER III - SICKLE CELL DISEASE

3.1 CLASSICAL VIEW

Sickle cell disease (SCD) IS a global health problem and the molecular mechanisms
leading to the manifestation of pain cnSIS and tissue injury are not completely
understood. The classical view of SCD focuses on the primary genetic defect due to the
substitution of valine for glutamic acid at the sixth position of the

~-globjn

chain that

produces HbS, which polymerizes when deoxygenated causing it to deform, become rigid
and obstruct blood flow causing acute and chronic tissue damage. This basic abnormality
is responsible for the diverse manifestations of sickle cell disease that result in recurrent
pain and progressive incremental infarction. Hypoxia induces polymerization of sickle
erythrocytes; however, there is no consensus on the events related to or following
erythrocyte sickling [10].

3~PATHOGENE~SOFSCD

HbS aggregates distort RBCs and cause them to lose their normal elasticity. Though
initially a reversible process, repeated episodes of sickling cause RBCs to lose their
elasticity on reoxygenation causing permanent damage. HbS polymerization and red-cell
sickling under deoxygenated conditions are central to the pathophysiology of this disease;
however, growing evidence indicates that SCD is a state of inflammation characterized
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by vascular endothelium activation and

incre~sed

blood cell-endothelium interactions

[11 ].

3.2.1

RED BLOOD CELLS AND HEMOGLOBIN

Red blood cells, or erythrocytes, carry oxygen and carbon dioxide between the lungs and
the extremities with flow driven by the heart. Erythrocytes are non-nucleated cells with
little genetic information. Hemoglobin is the protein contained within an erythrocyte that
oxygen and carbon dioxide molecules bind. Structurally, the normal adult hemoglobin
protein is made up of two a-chains and two

~-chains

forming a quaternary complex.

http://www. daviddarling. injolimageslhemoglohin jpg

Figure 5. Structural depiction of hemoglobin chains.

Conformational changes in the protein occur during transitions from oxygenated to
deoxygenated states. However, genetic defect in both copies of the

~-globin

gene

(homozygous) leads to the formation of HbS, or sickle hemoglobin, the root of SCD.
Point mutation in the

~-chain

produces a hydrophobic region in the tertiary structure of

the protein, leading to polymerization and sickling during deoxygenated conditions,
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becoming irreversible when flexibility is lost and preventing normal conformational
changes in the protein. These sickle cells initiate and continue to promote vasoocclusive
crisis, while newly formed red cells are also abnormal. Hence, treatment for the painful
episode is needed. A mutation in a single allele of the

~-globin

gene is known as sickle

cell trait and does not promote complications of SCD. Rather, sickle cell trait provides for
a heterozygote advantage to malaria, disrupting parasite incubation in erythrocytes. A
common therapy in SCD patients is attempt to boost fetal hemoglobin, or HbF, which
contains y-chains in place of

~-chains,

contributing to higher affinity for oxygen

molecules.

3.2.2

WHITE BLOOD CELLS

White blood cells, or leukocytes, are the defenders that compose the immune system.
Leukocytes, nucleated cells with valuable genetic information, consist of three main
categories: Granulocytes, Monocytes, and Lymphocytes. Granulocytes are large and
highly granulated leukocytes that make up the largest population of nucleated cells and
leukocytes. Categories of Granulocytes include neutrophils, eosoniphils, and basophils.
Because of their non-specificity in attacking of harmful substances, Granulocytes
generally arrive first at the scene of a crisis and eliminate threats by phagocytosis.
Monocytes are large leukocytes that circulate in the blood and mature to macrophages
upon crossing the endothelium and entering the tissue. These macrophages travel through
the lymphatic system and alert a specific immune response in the lymph nodes, pancreas
and spleen. Lymphocytes reside in these areas, smaller leukocytes that attack through
specific antigens on the membrane surface. Included in the lymphocyte category are T
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helper (Thl and Th2), Cytotoxic T lymphocytes (CTLs), T regulatory (Treg), Natural
Killer (NK) and B cells. Figure 6 shows several types of leukocytes. Neither mast cells
nor platelets are analyzed in the following studies of SCD. Mast cells reside in connective
tissue and are involved in allergic responses. Platelets are involved in blood clotting and
are pieces of larger cells called megakaryocytes.

http://www.gluegrant.org

Figure 6. Types of leukocytes found in immune system.

3.2.3

PHENOTYPE AND ACTIVATION MARKERS

Phenotype and activation markers were selected based on current literature. Both
phenotype and activation markers are molecules expressed on the membrane surface of
the respective cell and their presence can be detected by antibody staining. Particular
phenotype markers are expressed strongly on the respective cell and verify identity.
Activation markers are expressed based on stimulus and mediate in cell adhesion. Early
activation markers were used in these studies to elucidate conditions that initiate
vasoocclusive crisis, and include integrin and selectin molecules. These readily accessible
proteins subsist in vesicles near the cell membrane and become integrated quickly upon
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stimulus. In contrast, other activation markers proceed translation based upon gene
expression response and may take days to appear. Selectins are carbohydrate-binding
proteins that mediate adhesion of leukocytes to endothelial cells by forming loose bonds
that allow white blood cells to roll along the endothelium. Integrins, on the other hand,
are heterodimeric cell surface proteins that mediate adhesion of leukocytes to other
leukocytes, endothelial cells and extracellular matrix proteins through strong bonds. Also
spanning the cell membrane, integrins allow communication between the cell and its
environment. Table I describes phenotype (1 a) and activation (1 b) markers used in the
following seD studies [12].

Table 1

(a) Description of phenotype markers
Main Cellular

co Phenotype

Expression

Designation

C0133
C034
C061
C031

Description

Granulocyte

C0138
C036
C0146
C066b

Common EPC marker
EPe marker; cell-celt adhesion; binds L-selectir:
Integrin subunit; Forms Ee, WBC, and platelet aggr~gates
Platelet Endothelial cell adhesion molecule (PECAM-l)
Vascular Endothelium Grow Factor Receptor
EPC marker
Monocyte/Microvascular EC
Common endothelium/mature EC marker
Granulocytes

Monocyte/Macrophage

C014

Monocytes/Macropnages

C03
C04
C025
C019
C056
C045

. H{T2 helper cells
Cytotoxic T Lymphocytes
T regulatory cell
B cell
Natural Killer cell
leukocyte Comm()11 Antigen

Endothelial Progenitor

. VEGFR2

Endothelia! Mature

lymphocyte

leukocyte
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(b) Description of activation markers
Main
Cellular
Expression
Endothelial
Mature
Lymphocyte

Monocyte &
Granulocyte

3.2.4

CD
Activation
Designation

CD62P
CD106
CD54
CD69
CD1a
CD64
CD49d
CD18
C0162

Description
P-selectin; Leukocyte adhesion to endothelium via CD162
Vascular Cell Adhesion Molecule (VCAM-l); ligand fo:- CD49d/CD29
Intracellular Adhesion Molecule (ICAM-.1); ligand for CDllb/CD18
Activation Inducer Molecule

................................ , ..

Major Histocompatibility Complex (MHC) I-like
Role in phagocytosis
Monocyte/T cellintegrin subunit; binds to VCAM
Granulocyte/Monocyte Integrin subunit; Binds ICAM
P-selectin a1ycoprotein ligand-l

CD62L

L-selectin; Leukocyte-endothelial adhesion

CD61
CDl1b

............................ Integrin subunit
Granulocyte/Monocyte Integrin subunit; Binds ICAM

HLA-DR

MHC Complex II

POTENTIAL INTERACTIONS LEADING TO VASOOCCLUSION

Patients with SCD have abnormally high baseline leukocyte counts. Severity of SCD
increases with leukocyte count [11]. Recent in vivo studies suggest that adherent
leukocytes bind RBCs and contribute to the microvascular pathology that characterizes
sickle cell disease (SCD), although the precise mechanism is not known. Mice expressing
the trait for human sickle hemoglobin showed that sickle RBCs bind to adherent
leukocytes in inflamed venules, contributing to vasoocc1usion [13]. In vivo studies show
that leukocyte subpopulations from sickle patients capture more RBCs per interacting
leukocyte than the corresponding subpopulations from healthy controls. All leukocytes
including lymphocytes, monocytes and neutrophils interact with sickle RBCs [14.1;
however, neutrophils are thought to contribute the most to vasoocclusive crisis due to
high numbers in circulation [11].
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Leukocyte-RBC interaction is not the cause ofvasoocc1usion, but rather the adherence of
leukocytes to the endothelium impedes blood flow. Activated leukocytes send signals to
endothelial cells (ECs), in tum activating the ECs and promoting adherence. Binding of
monocytes to sickle cells, for instance, activates the vascular endothelium causing
adhesion and leads to vasoocclusive crises [15]. Leukocyte subpopulations from sickle
patients are also more adherent to ECs than healthy controls [14]. Transgenic sickle mice
deficient in P- and E-selectins, which thwart leukocyte adherence to the vessel wall, are
protected from vasoocclusion [13]. Hence, activation of leukocytes and the endothelium
plays an important role in SCD.

3.3 SYMPTOMS AND COMMONLY PRESCRIBED TREATMENTS
Included in this section are characteristics that classify the three types of patients samples
used in the studies found in this thesis. Commonly prescribed treatments for

seD patients

with vasoocclusive episodes are also examined.

3.3.1

CHARACTERISTICS OF PATIENT SAMPLES

Patients in the clinical studies with the microfluidic lysis device are classified into three
groups: healthy controls, mild phenotype SCD and symptomatic SCD. Healthy volunteers
in this study were individuals between the ages of 20 to 60 who have no copy of the allele
for sickle cell trait. Although using patients with a single copy of the allele may seem
ideal for healthy controls, obtaming such volunteers is very difficult. In addition, a
difference in expression of phenotype or activation markers between individuals with no
copy of the allele and those with two copies is more significant. Mild phenotype SCD
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..

patients, ages 10 to 19, contain both copies of the HbS allele but are not currently
experiencing any complications of va so occlusive crisis. Symptomatic SCD patients, also
ages 10 to 19, contain both copies of the HbS allele and are receiving pheresis treatment
for recurring, painful complications of vasoocc1usive crisis. Blood from these individuals
was drawn prior to pheresis, with treatment received every 3 to 5 weeks while episodes
persist. Clinical complications from vasoocclusive crisis include severe pain, acute chest
syndrome, primary and secondary stroke, priapism and pulmonary hypertension.

3.3.2

HYDROXYUREA

One common treatment option for SCD patients includes hydroxyurea. Toxic to
proliferating, cells, hydroxyurea inhibits the enzyme ribonucleotide reductase from
producing deoxyribose sugars in DNA [16]. Hence, the drug does not actually decrease
adhesion of leukocytes to RBCs or ECs by lowering activation markers; rather,
hydroxyurea prevents occurrences of vasoocclusion by limiting the number of leukocytes
and RBCs in the blood [17]. Lowering the baseline leukocyte count is critical for
reduction of crises in SCD.

3.3.3

PHERESIS

Pheresis is another commonly prescribed treatment for symptomatic SCD patients. In this
process blood is removed from the body to filter out particular components by density
differences. Erythrocytes are exchanged in the case of SCD to rid of sickle cells
participating in new vasoocclusive events, to provide added oxygen-canying capacity

2S

and to decrease blood viscosity. Donor erythrocytes are transfused with other components
of the blood and returned into circulation.
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CHAPTER IV - STUDY OF HEALTHY CONTROLS AND MILD PHENOTYPE
SCD

4.1 INTRODUCTION
In

thisstudY,,~I~od

was sampled from healthy controls (n = 3) and mild phenotype SCD

patients (n = 3). Each sample was analyzed with micro fluidics, NH 4 C) mediated lysis and
Ficol density gradient separation. Once the effectiveness of this device was established in
a clinical setting as compared to currently available lab techniques, the panel of activation
markers was expanded and a comparative approach was taken to analyze samples from
healthy controls (n

=

6) and mild phenotype SCD patients (n

=

6) using only the

microfluidic lysis device. Results were published in the journal Biomedical Microdevices
[18].

4.1.1

MOTIVATION FOR STUDY

This protocol has been validated in the laboratory and pre-clinical settings. However,
demonstration of the potential of this device to enrich leukocytes in the clinical setting to
understand disease processes has not been accomplished. In this study the clinical
effectiveness of the microfluidic protocol to deplete erythrocytes (sickle and nonna]),
produce high leukocyte yield and minimize artifactual activation was compared to
conventional techniques using

seD as an example. The
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ability of this protocol to

accurately determine leukocyte differential counts and their activation status in mild
phenotype SCD and healthy controls was verified.

Several epidemiological studies have implicated abnormally high baseline leukocyte
counts in SCD patients as a major risk factor in the development of disease related
complications, with severity increasing with leukocyte count [11]. As a result, the role of
sickle erythrocytes in SCD has been redefined as an irritant that provokes an
inflammatory response along with activation of the endothelium [15]. Few studies have
sought to understand the comprehensive effects of leukocytes and their activation status
in the initiation of vasoocclusion, and all of these that have utilized conventional
leukocyte enrichment protocols [19]. Accurately determining leukocyte yield and
activation within homozygous SCD patients will help in the understanding and treatment
of this genetic disease.

4.2 MATERIALS AND METHODS

This study was done in collaboration with Dr. Ashok Raj and Dr. Salvatore J. Bertolone
at the center for Pediatric Hematology/Oncology, School of Medicine, University of
Louisville. Facilities at the Flow Cytometry Core, James Graham Brown Cancer Center,
University of Louisville were utilized to run samples, assisted by Dr. Sam Wellhausen.
The following section briefly explains the process by which the experiments were carried
out during this study. It includes details on patient classifications~ protocols for
conventional and micro fluidics lysis enrichment techniques and flow cytometry sample
and data analysis.
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4.2.1

BLOOD SAMPLES

Blood collection was approved by the Institutional Review Board of the University of
Louisville. After obtaining written consent, 4 mL of blood were drawn from a total of 9
healthy volunteers and 9 mild phenotype SCD patients (n = 3 for initial study and n = 6
for expanded panel of antibodies) with sodium heparin as anticoagulant (Vacutainer™,
Becton Dickinson, Franklin Lakes, NJ).

4.2.2

SAMPLE CLASSIFICATION

Healthy volunteers in this study were between the ages of 20 to 60, did not have a copy
of the allele for SCD and were not of any particular race. Mild phenotype SCD patients
contained copies of both alleles of the sickle cell trait. Patients were of African-American
descent between the ages of 10 to 19 with no vasoocclusive crisis. Refer to section 3.3 for
more details on patient sample classification.

4.2.3

STANDARD NH 4 CL MEDIATED LYSIS PROTOCOL

Blood samples were extracted and mixed with erythrocyte lysis buffer (Fischer Scientific,
Florence, KY) in a ratio of 1: 15 and mixed thoroughly by vortexing for 5 minutes. The
sample was then spun down in a refrigerated centrifuge at 4°C for 10 minutes at 400g.
The supernatant was discarded and the pellet was resuspended in flow cytometry buffer
for further analysis.
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4.2.4

STANDARD FICOL DENSITY GRADIENT SEPARATION

1 mL of blood sample was diluted with 2 mL of IX phosphate buffered saline (PBS) and
then layered gently on top of Ficol density gradient separation medium (GE Healthcare,
Bio-Sciences AB, Uppsala, Sweden) in a 15 mL conical tube. This was then spun down
at 500g for 30 minutes in a refrigerated centrifuge at 4°C. The first layer containing·
platelet rich plasma was discarded, the second layer (white band) containing the
peripheral blood mononuclear cells (PBMCs) was fractionated, the third layer of Ficol
solution was discarded and the pellet containing polymorphonuclear cells (PNMs) and
erythrocytes was enriched and subject to NH4 CI mediated lysis protocol for elimination
of erythrocytes. The PBMCs and PNMs were then combined together in flow cytometry
buffer for flow cytometric analysis.

4.2.5

MICROFLUIDIC LEUKOCYTE ENRICHMENT

A micro fluidic lysis device similar to the device described by Sethu et al [20] was used
for enrichment of leukocytes and circulating nucleated cells from whole blood. Briefly,
the device allows for whole blood to rapidly mix with deionized water in a 1:30 ratio for
about 10 seconds in a micro fluidic channel, which is sufficient for complete lysis of
erythrocytes. The remaining cells are returned to isotonic conditions at the exit of the
device and fixed using 2% paraformaldehyde (PFA). Following centrifugation to remove
erythrocyte debris, the remaining leukocytes were suspended in a flow buffer containing
1% bovine serum albumin (BSA), 1% PFA and 0.1% sodium azide for staining and flow
cytometry. Refer to section 2.4 for an in depth protocol of the microfluidic lysis device.
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4.2.6

CELL COUNTS AND FLOW CYTOMETRIC ANALYSIS

For each leukocyte-enriched sample, total cell counts following lysis were obtained using
a Cellometer™ (Nexce1om, Lawrence, MA), automated cell-counting system. Each
sample was counted twice and averaged to obtain the total cell counts. Different
subpopulations were then assessed by flow cytometry. Cells were visualized using
peridin chlorophyll-a (PerCP), fluorescein isothiocyanate (FITC), phycoerythrin (PE) and
allophycocyanin (APC) conjugated antibodies (BD Biosciences, San Jose, CA) against
leukocyte phenotype and activation cell-surface markers (Table 2). Conjugated antibodies
VEGF R2/KDR (R&D Systems, Minneapolis,MN) and CD133 (Ancell Co., Bayport,
MN) were also used to visualize endothelial cells. Stained cells were washed in 1% HAB
(Hank's balanced salts without calcium or magnesium, plus 1% bovine serum albumin,
0.1 % sodium azide, and 1mM ethylenediamine tetraacetic acid), pelleted, resuspended in
HAB, and analyzed on a FACSCalibur™ flow cytometer (BD Biosciences, San Jose,
CA), using CellQuest™ software (BD Pharmingen). Cell activation was scored using the
Rank Sum Test. All data correspond to the means of cell concentration or fluorescence
intensity, ± S.E.M., for controls (n = 6) and mild phenotype SCD (n = 6).

4.2.7

FLOW CYTOMETRY DATA ANALYSIS

Flow cytometry data files were analyzed using WinMDI software (Scripps Institute, Flow
Cytometry Core Facility, San Diego, CA). Each data file was manually gated and
analyzed using different .combinations of phenotype and activation markers. All
fluorescence expression was normalized using controls and is represented as mean
fluorescence intensity (MFI) in arbitrary units.
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Table 2

Cell Types with corresponding phenotype and activation markers
Cell Iype
. . Granulocytes
Granulocyte sub-population

Monocytes
MonocytesIMacrophages
Myelocytes
Th1 and Th2

en

B celis·
T-reguJatory,cells ..
Natural Killer cells.
Mature Endothelial ceJJ

Progenitor Endothelial ceMs

Phen,otype Marker
CD66+
CD&6+/CD49d+
CD14+
CD36+
CD11 b+!CD66+ICD49d+
CD4+!CD3+
CD4-/CD3+
CD~!CD25-lCD56--/CD3-

CD4+ ICD25+
CD56+
CD146+/CD36+
CD146+/CD31+
CD133+/CD34+
VEFG R2+
VEGF R2+!CD34+
VEFG R2+!CD133+

Cell Type

Activation Marker
CD18
Granulocytes
CD11b
CD18
Monocytes.
CD11b

HLA-DR
CD1a

CD62P
Endothehal GeNs'

CD106
CD36
CDM

4.3 RESULTS

This section summarizes the results comparing the micro fluidics protocol to conventional
techniques in terms of cell loss and artifactual activation. Comprehensive analysis using
the microfluidic protocol is also presented. Graphs and tables are provided.

4.3.1

ERYTHROCYTE DEPLETION AND LEUKOCYTE YIELD

Blood samples were drawn from healthy controls and mild phenotype SCD patients and
leukocytes were enriched using micro fluidic lysis, conventional NH 4 Cl mediated lysis
and Ficol density gradient separation. Circulating nucleated cells were phenotyped using
fluorescently labeled antibodies as CD3+CD4+ Thl and Th2, CD3+CD4- CTL, CD19+
B cells, CD14+ Monocytes and CD66b+ Granulocytes and evaluated using 4 color flow
cytometry. Results in actual cell counts per mL of whole blood (Figure 7) indicate that
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micro fluidic leukocyte enrichment resulted in significantly higher cell yield for all cell
types in both healthy controls and mild phenotype SCD patient samples. Also, flow
cytometry confirmed absence of erythrocytes or erythrocyte debris.

100
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60 •

Mild Phenotype SCD

I
1•.........

I

oj ..

1 ....

-,-II1II '.___,-______ ... ,

• Microfluidics
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Figure 7. Comparison of leukocyte yield between enrichment techniques.

4.3.2

LEUKOCYTE ENRICHMENT PROCESS INDUCED ACTIVATION

Phenotyped leukocytes using each of the aforementioned techniques were evaluated for
expression of early activation markers. Lymphocytes were not scored for activation as T
and B Lymphocyte activation typically requires > 24 hours and most enrichment
protocols last

~

30-60 minutes. Cells enriched using Ficol density gradient separation

were also not scored, since Granulocytes enriched via Ficol density gradient separation
require NH4 CI mediated lysis to eliminate contaminating erythrocytes. Therefore we
compared expression of early activation markers in Monocytes and Granulocytes
enriched using microfluidics and NH 4 CI mediated lysis. Monocytes were analyzed for
expression of integrins CD 11 b and CD 18 and Major Histocompatibility Complex II
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(HLA-DR) whereas granulocytes were analyzed for expression of integrins CDI! band
CD18. Results (Table 3) indicate lower expression of early activation markers following
enrichment with micro fluidics for both healthy controls and mild phenotype SCD
samples.

Table 3

Comparison of activation between enrichment techniques
MI d Phenotwe S CD

Healthy Controls
MNn
CI}U.
Monocytes

CD6Gb*

GIQlllllo~.$

4.3.3

emit

CDHb~'
fILA-Oft.. .

CD?'.,

GDl1b.·

07.82:;

3.14

331.!}(:

55.4{·

2.4ei)
£6.51
317.01

SfM

SEM· 'Mi,II,'w

(') 3()
4.77
110.38.
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lysis
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SCM
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2:1.)1

134.65

6.@

72tH!)
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513.52
0.32

.%h.141

2.35·
CUi'

77.82
544.45

i3.00
i64.oo

227
48. 74

2.30

160.2"1

42.zt.

SEM

100.72
00397

jfj.f6
rJ4.513

2.4$

022

65.49
39>l.fIJ

134.12

13.00

COMPREHENSIVE EVALUATION OF LEUKOCYTE ACTIVATION
MARKERS IN SCD

Controls and mild phenotype SCD samples were analyzed comprehensively using the
microfluidic enrichment protocol. Leukocytes and other circulating nucleated cell
populations were phenotyped and their counts were determined. Activation markers for
several leukocyte and circulating endothelial cell populations were also measured.
Circulating nucleated cells were phenotyped and split into the following panels:
Lymphoid (Figure 8), Myeloid (Figure 9), Mature Endothelial and Endothelial Progenitor
(Figure 10).

Lymphoid panel included CD3+CD4+ Th 1 and Th2, CD3+CD4- CTL,

CD4+CD25+ Treg, CD56+ NK and CD4-CD25-CD56-CD3- B cells. Myleoid panel
consisted

of

CD66b+CD49+

CD66b+
Granulocyte

Granulocytes,
subpopulation,
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CD 11 b+CD66b+CD49+
CD14+

Monocytes

Myelocytes,
and

CD36+

MonocyteslMacrophages. Mature Endothelial panel included CDI46+CD36+ and
CDI46+CD31+. Progenitor Endothelial panels consisted of CDI33+CD34+, VEGF
R2+CD133+, VEGF R2+ and VEGF R2+CD34+. Expression of activation markers
(Figure 11) was quantified for CDIIb, CDI8 and HLA-DR on Monocytes, CDllb and
CDI8 on Granulocytes, CDla on Lymphocytes and ICAM-I (CDS4), VCAM-I
(CDI06), P-Selectin (CD62p) and CD36 on circulating endothelial cells.
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Figure 8. Lymphoid panel.
Myeloid Panel
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Figure 9. Myeloid panel.
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Figure 10. Endothelial panel.

Figures 8-10 show comparisons of actual cell counts per mL of whole blood in controls
and mild phenotype SCD patients. From the data it can be seen that the leukocyte
(lymphoid and myeloid) and circulating endothelial counts (mature and progenitor) are
higher in mild phenotype SCD patients. There is no selective increase in any subpopulation; rather, there are proportional increases of about 2 fold in all subpopulations.
Exceptions include B cells, Myelocytes and the Granulcoyte subpopulation where there
was a 3-4 fold increase. Figure 11 shows the comparison of various activation markers
between the two groups. Results show that there is no statistically significant increase
(Rank Sum Test) with a confidence of p = 0.05 in expression of activation markers
between the groups.
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Figure II. Activation of nucleated cells.

4.4 DISCUSSION

seD serves as an excellent model to show the superiority of the micro fluidic protocol as
a sample preparation technique toward clinical studies. Published literature indicates that
seD patients have abnormally high leukocyte counts in peripheral blood and that
activation markers are expressed during periods of vasoocclusive crisis. Leukocytes also
interact with the damaged endothelium layer and may contribute to vasoocclusion [19].
With many cell types present in the pathogenesis of SeD, it is important to accurately
determine those playing a major role. By analyzing the activation status and gene
expression profile of the circulating cell populations in seD patients, the mechanism of
vasoocclusion can be realized and treated. Sample preparation technique without cell loss
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and artifactual activation will therefore have a significant impact on the interpretation of
the data attained from a study.

Results comparing the microfluidic protocol to NH 4 CI mediated lysis and Ficol density·
gradient separation have been presented. Minimal loss and artifactual activation of
circulating cell popUlations were exhibited and graphical comparison is shown in Figure
7 and Table 3, respectively. Microfluidics proved to be superior for use in SeD patients.
Next the panel was expanded and the microfluidic protocol was used to comprehensively
profile the circulating cell populations in mild phenotype SCD patients. Markers for
leukocytes and circulating endothelial cells were obtained from literature as the most
widely used for each population in terms of phenotype and activation using flow
cytometry [21-25]. Results from this part of the study indicate that mild phenotype SCD
patients have a non-selective increase in leukocyte counts as compared to healthy
controls, as shown in Figures 8 and 9. Increase in mature and progenitor endothelial cells
was not significant, depicted in Figure 10. The most substantial result, illustrated in
Figure 11, shows no statistical difference in activation between mild phenotype SCD
patients and healthy controls.

Significance of this data can be interpreted in terms of the role of leukocytes in
vasoocclusive crisis in SCD patients. SCD patients in this study were mild phenotype and
not in a state of pain crisis. However, leukocyte levels were still elevated compared to
controls, although not activated. This study therefore provides evidence that leukocytes in
mild phenotype SCD patients are not in a chronic state of inflammation; rather high
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leukocyte counts represent a state, highly favorable for development of an inflammatory
response in reaction to a given stimulus. As for circulating endothelial counts, both
mature and progenitor endothelial cells were not activated in SCD patients compared to
controls. Circulating mature endothelial cells were most likely present due to damage and
displacement from the blood draw or from sickle erythrocytes damaging the endothelium
layer. Very few, inactivated progenitor endothelial cells were found in circulation.
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CHAPTER V - STUDY OF MILD PHENOTYPE SCD AND SYMPTOMATIC
SCD

5.1 INTRODUCTION
In this study blood was sampled from mild phenotype (n

=

11) and symptomatic seD

patients (n = 11). Each sample was enriched for nucleated cells using the microfluidic
lysis device and analyzed using flow cytometry. The panel of activation markers was
expanded from the previous study. A similar comparative approach was taken to analyze
samples from mild phenotype and symptomatic SCD patients.

5.1.1

MOTIVATION FOR STUDY

Clinical potential of this device to enrich leukocytes and understand disease processes is
tested. In the previous study a baseline leukocyte count and activation status was set for
healthy controls and mild phenotype SCD patients [18]. The objective of this study was
to compare percentage of nucleated cell populations and activation of these populations
between mild phenotype and symptomatic SCD patients. Using the microfluidic lysis
device to enrich nucleated cell populations and flow cytometry analysis, a direct
comparison between the two categories of SCD patients was made to search for a
possible marker that may indicate and/or playa role in the onset of vasoocclusive crisis.
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Several studies have been carried out comparing mild phenotype and symptomatic SCD
patients. With no consensus on the events leading up to a vasoocclusive crisis [10],
several articles have suggested the importance of epigenetic effects on the mutated

~

globin gene in SCD that produces extreme variability in clinical expression among
individuals [14, 26-28], while others have proposed the importance of certain expression
markers on leukocyte popUlations that may indicate the inevitability of a painful episode
[13, 15, 19, 29]. By staining for these possibly relative expreSSIOn markers, each
population of nucleated cells was examined according to phenotype, accomplishing
enrichment with the micro fluidic lysis device, to determine if a difference in expression
between groups or individuals exists. Other studies analyzing expression markers utilized
conventional techniques for enumeration, therefore prone to cell loss and artifactual
activation, skewing results and deduced conclusions [11]. Hence, clinical expression of
markers among individuals may be too variable to investigate. Accurately determining
activation status of nucleated cell populations among mild phenotype and symptomatic
SCD patients will aid in the comprehension and prevention of vasoocclusive crises.

5.2 METHODS
This study was done in collaboration with Dr. Ashok Raj and Dr. Salvatore J. BertoJone
at the center for Pediatric Hematology/Oncology, School of Medicine, University of
Louisville. Facilities at the Flow Cytometry Core, James Graham Brown Cancer Center,
University of Louisville were utilized to run samples, assisted by Dr. Sam Wellhausen.
The following section briefly explains the process by which the experiments were carried
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out during this study. It includes patient classifications, protocol for the microfluidic lysis
enrichment and flow cytometry sample and data analysis.

5.2.1

BLOOD SAMPLES

Blood collection was approved by the Institutional Review Board of the University of
Louisville. After obtaining written consent, 4 mL of blood were drawn from a total of 11
mild phenotype and 11 symptomatic SeD patients with sodium heparin as anticoagulant
(Vacutainer™, Becton Dickinson, Franklin Lakes, NJ).

5.2.2

SAMPLE CLASSIFICATION

Mild phenotype SeD patients contained copies of both alleles of the sickle cell trait and
were of African-American descent between the ages of 10 to 19 with no vasoocclusive
crisis. Symptomatic SeD patients were receiving pheresis treatment for vasoocclusive
episodes. Refer to section 3.3 for further details on patient sample c1assit'ication.

5.2.3

MICRO FLUIDIC LEUKOCYTE ENRICHMENT

A micro fluidic lysis device similar to the device described by Sethu et al [20] was used
for enrichment of leukocytes and circulating nucleated· cells from whole blood. The
device allows for whole blood to rapidly mix with deionized water in a 1:30 ratio for
approximately 10 seconds. Detailed theory, mechanism and protocol for the device can
be found in section 2. The remaining cells are returned to isotonic conditions at the exit
of the device and fixed using 2% parafonnaldehyde (PFA). Following centrifugation to
remove erythrocyte debris, the remaining leukocytes were suspended in a flow buffer
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containing 1% bovine serum albumin (BSA), 1% PF A and 0.1 % sodium azide for
staining and flow cytometry.

5.2.4

FLOW CYTOMETRIC ANALYSIS

Different subpopulations were assessed by flow cytometry. Cells were visualized using
peri din chlorophyll-a (PerCP), fluorescein isothiocyanate (FITC), phycoerythrin (PE) and
allophycocyanin (APC) conjugated antibodies (BD Biosciences, San Jose, CA) against
leukocyte phenotype and activation cell-surface markers. Conjugated antibodies VEGF
R2/KDR (R&D Systems, Minneapolis, MN) and CD133 (Ancell Co., Bayport, MN) were

also used to visualize endothelial cells. Refer to Table 4 for list of markers. Stained cells
were washed in 1% HAB (Hank's balanced salts without calcium or magnesium, plus 1%
bovine serum albumin, 0.1 % sodium azide, and 1mM ethylenediamine tetraacetic acid),
pelleted, resuspended in HAB, and analyzed on a FACSCalibur™ flow cytometer (BD
Biosciences, San Jose, CA), using CellQuest™ software (BD Pharmingen). Cell
expression was scored using the Rank Sum Test. All data correspond to the means of
total percentage of cells or relative high percentage ofregioned populations, ± S.E.M., for
mild phenotype (n = 11) and symptomatic SCD (n = 11).
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Table 4

Nucleated cell populations and corresponding phenotype and activation markers
Cell Type

Cell Type

Phenotype Marker
C034+/CD133+/C061+

Endothelial Progenitor

C034+/C0133+/C031+

Activation Marker

C0106
Endothelial Mature

CD62P

C034+/C0133+/VEGFR2+

C054

C034+/C0133+/C0138+

CD64

Endothelial Mature

C0146+/C031+/CD36+

CD49d

Granulocyte

C066b+

Monocyte/Macrophage

CD14+

CD62l

C03+/C04+

cow (Mon)

C03+/C04-

C061 (Gran)

Lymphocyte

Monocyte/Granulocyte

Lymphocyte

C025+/C04+
WBC

5.2.5

C0162

C069

C045+

FLOW CYTOMETRY DATA ANALYSIS

Flow cytometry data files were analyzed using WinMDI software (Scripps Institute, Flow
Cytometry Core Facility, San Diego, CA). Each data file was manually gated and
analyzed using different combinations of phenotype and activation markers. All
fluorescence expression was normalized using controls and is represented as a percentage
of nucleated cells in venous circulation.

5.3 RESULTS

This section summarizes the results of the expanded panel of antibodies to study the
pathogenesis of SCD using the microfluidic protocol. Graphs and tables are provided.
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5.3.1

ERYTHROCYTE DEPLETION AND LEUKOCYTE YIELD

Blood samples were drawn from mild phenotype and symptomatic SCD patients and
leukocytes were enriched using microfluidic lysis. Leukocytes and other circulating
nucleated cell populations were phenotyped and their percentages were determined.
Circulating nucleated cells were phenotyped and split into the following panels:
Leukocytes (Figure 12) and Endothelial (Figure 13). Leukocytes were phenotyped using
fluorescently labeled antibodies as CD3+CD4+ Thl and Th2, CD3+CD4- CTL,
CD4+CD25+ Treg cells, CD 14+ Monocytes, CD66b+ Granulocytes and CD45+
Leukocytes. Endothelial panel included Mature Endothelial CD 146+CD36+CD31 + and
Progenitor

Endothelial

CDI33+CD34+CD61+,

CD 133+CD34+CD31 +,

CDI33+CD34+CD138+ and CD133+CD34+VEGF R2+. Panels were evaluated using 4
color flow cytometry. Results in percentage of total nucleated cells (Figures 12-13)
indicate that no definitive difference can be seen (p 2: 0.05) between mild phenotype and
symptomatic SCD patients.
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Figure 12. Leukocyte phenotype panel.
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Endothelial Phenotype
14

• Symptomatic

0 Mild Phenotype

Figure 13. Endothelial phenotype panel.

5.3.2

LEUKOCYTE ACTIVATION MARKERS IN SCD

Mild phenotype and symptomatic SCD samples were analyzed comprehensively using
the micro fluidic enrichment protocol. Activation markers for several leukocyte and
circulating endothelial cell populations were measured. Expression of activation markers
was quantified for CD64, CD49d, CDI8, CD162 and CD62L on Monocytes (Figure 14),
CD64, CD49d, CD61, CD162 and CD62L on Granulocytes (Figure 15), CD69 on
Lymphocytes (Figure 16) and ICAM-l (CD54), VCAM-l (CD106) and P-Selectin
(CD62p) on circulating Endothelial Cells (Figure 17).
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Figure 15. Granulocyte activation paneL
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Figure 17. Endothelial activation panel.

Figures 12-13 show comparisons of percentage of total nucleated cells in mild phenotype
and symptomatic

seD patients. From the data it can be seen that there is no significance

between leukocyte (lymphoid and myeloid) and circulating endothelial counts (mature
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and progenitor). However, there is a large variance among patient samples; hence, Table
5 depicts percentage of total nucleated cells (Leukocyte and Endothelial) ranging from
high to low. Figures 14-17 show the comparison of various activation markers between
the two groups, based on Leukocyte and Endothelial sUbpopulations. Results show that
there is no statistically significant increase (Rank Sum Test) with a confidence of p :::::
0.05 in expression of activation markers between the groups, with the exception of a
significant difference (Figure 14) of CD62L expression on Monocytes (p < 0.01). Since
there is still a large variance among patient samples, Table 6 depicts percentage of
regioned nucleated cell populations (Leukocyte) ranging from high to low.

Table 5

Ranked values of percentage of total nucleated cells
Avg

Highest to Lowest
CD66b+
C014+
%

Total

CD3+/C04f-

Cells
CD3+/C04·
C025+/C04+

Symptomatic 27.51 19.08 11.14 W.67

8.06

8.02

7.73

6.62

5.31

3.87· 3.00 10.09 2.13

Mild Phenotype 18.39 17.14 12.49 9.29

6.68

5.62

4.83

2.62

2.60

2.20

1.85

7.61

1.81

6.54

6.30

5.87

5.43

4.46

3.32

2.51

6.10

0.66

Symptomatic 10.26

C034+/COB3+/
C031+

%
Total

cells

CD34+/C0133+/
VEGFR2+
CD34+/C0133+1
C0138+
C0146+/CD31+/
C036+
CD45+

7.75

7.33

7.33

8.41

8.22

6.97

5.48

4.75

2.67

2.22

8.19

1.30

6.03

5.99

5.45

5.44

5.35

4.31

3.21

3.07

2.38

5.47

0.66

Mild Phenotype 13.76 12.59 9.30

9.11

8.15

7.00

6.44

6.14

5.54

3.01

1.95

7.55

1.08

1.36

1.27

1.04

0.98

0.85

0.74

0.65

0.20

1.03

0.12
0.49

Mild Phenotype 14.87 13.64 12.95 9.85
Symptomatic 9.45 .9.03
Symptomatic 1.43

1.41

1.39

Mild Phenotype 4.79

4.16

3.24

1.49

1.83

1.25

0.55

0.51

0.49

0.47

0.22

1.82

Symptomatic 14.94 10.71 6.81

6.70

4.70

4.30

3.64

3.53

3.08

0.85

0.18

5.40

1.30

11.17 6.21

3.22

3.03

2.00

1.70

0.53

0.37

0.27

5.72

1.96

6.73

4.79

4.70

3.69

3.60

3.10

1.15

0.21

5.50

1.28

Mild Phenotype 17.59 16.92 11.26 6.75

3.71

3.11

2.37

1.78

0.51

0.38

0.30

5.88

1.95

6.48

5.01

4.26

3.50

1.66

1.58

8.57

2.47

CD34+/C0133+/

CD61+

SEM

Symptomatic 70.64 68.85 61.34 56.51 51.59 47.13 45.25 44.27 30.17 29.55 24.22 48.14 4.73
Mild Phenotype 76.34 67.43 66.12 61.19 57.70 55.85 52.59 46.22 42.40 35.89 34.09 54.17 4.06

Mild Phenotype 17.60
...

16.n

Symptomatic 14.97 10.76 6.81

9.45

7.93

7.13
6.9Q

6.23

6.19

3.84

1.82

0.98

0.34

7.26

2.16

Symptomatic 28.82 18.12 9.59

7.11

6.96

6.47

4.97

3.76

3.49

1.51

1.45

8.39

2.47

Symptomatic 28.82 18.51 9.96
Mild Phenotype 26.55

9.66

7.40

Mild Phenotype 24.81 9.34

8.99

7.33

5.70

6.19

5.10

3.81

1.97

0.91

0.29

6.95

2.01

o.n

0.69

0.46

0.37

0.37

0.36

0.21

0.19
{j.18

0.12

0.11

0.41

0.08

Symptomatic 0.85

{j.10 0.09 0.45 0.11
0.58 0.54 0.49 0.49 0.47 0.37 0.19
Symptomatic 92.27 91.01 89.53 &5.31 81.88 78.50 75.72 74.02 70.90 69.88 67.76 79.71 2.67

Mild Phenotype 1.39

Mild Phenotype 96.43 93.10 92.96 90.34 89.61 79.06 73.90 73.84 72.47 61.89 51.42 80.46 3.83
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Table 6

Ranked values of percentage of regioned nucleated cell populations
Avg
Symptomatic 23.18

7.57

5.56

2.08

1.81

1.74

1 ..59

1.36

0 ..59

0 ..55

4.94 2.00

Mild Phenotype 17.17
Symptomatic. 19.46

9.26
19.38

4.33
16.38

2.79
12.77

1.83
11.04

1.65
8.05

0.99
7.10

0.64
4.48

0.55
4.17

0.50
1.89

0.45
1.15

3.65 1.56
9.62 2.01

, Mild Phenotype 72.66

40.42

33.69

28.73

16.79 16.16 15.06 12.34 6.98

5.06

4.81 22.97 6.10

Symptomatic 99.56

98.82
97.89

97.12 97.10
96.37 92.85

96.34 96.11 95.06 93.92 89.64.85.77.81.71 93.74 1.71
88.82 86.99 84.32 78.03 72.6.5.60.58. 29.53 80.55' 6.18

89.08

88.74

87.79

85.80 &2.89 81.14 77.82 71.75 68.43 50.89 79.59 3.02

83.63
16.35
16.66

82.70

80.41

15.48
9.40

13.98
9.25

78.25 69.93 68.88 56.53 52.01 50.92 24.41 67.16 5.90
8.18 7.62 6.63 5.37 4.54 4.22 3.59 10.30 2.20
9.06 8.46 7.10 6.64 4.27 4.14 3.79 9.90 2.29

99.35

99.21

97.73

97.72

97.52 97.45 97.31 96.50\ 96.07 93.12 89.52 96.50 0.86

Mild Phenotype 99.81
Symptomatic. 99.85

97.98
99.85
99.82

97.97
99.64
99.61

97.60
99.58

96.41 96.39 94.62 92.91 90.22 89.47 80.37 93.98 1.68

99.17

Symptomatic 100.00 99.82
Mild Phenotype 100.00 100.00

99.62

99.60 ·99.50 99.39 99.17 98.94 98.46 98.02 94.62 98.83 0.46

COM
C061
%
Granulocytes

CD162
CD62l
CD49d·
C064
C018

% Monocytes C0162
C062l

SEM

8.26

Mild Phenotype 97.99
Symptomatic 91.18
Mild Phenotype 91.04
Symptomatic 27.36
Mild Phenotype 30.12
symptomatic

Mild Phenotype 100.00

Symptomatic 91.96

89.26

Mild Phenotype 69.91 67.04
Symptomatic 98.81 98.02
CD49d
Mild Phenotype 98,49 98.43

99.54 99.30 98.94 98.6.5 9.5.04 94.66 94.22 98.12 0.68
98.66 98.50 98.03 97.57 97.14 95.38 94.66 98.05 0.53

99.72 99.61 99.34 98.15 97.94 97.44 97.35 96.66 93.69 98.17 0.57
88.14 87.50 84.6.5 70.93 58.73 56..54 40.33 32.11 2.39 63.87 S.78
52.35 35.92 31.13 27.69 26.74 23.48 10.07 2.94 . 2.11 31.76 7.03
96.07
98.28

93.06
96.49
98.47

91.63 91.53 91.52 91.23 90.86.85.09 84.73 92.05 1.36
94.02 90.51 89.72 84.55 84.22 84.13 83.87 91.16 1.88
98.09 97.00 96.30 88.20 85.98 85.71 81.58 93.72 2.08
92.78 91.67 90.98 83.27 82.81 82.68 71.43 89.40 2.57

Symptomatic 100.00 100.00 99.60
Mild Phenotype. 100.00 99.65 94.32 93.81
% Endothelial
symptomatic 100.00 100.00 9955 99.45 98.94 98.25
C062P
Cells
Mild Phenotype 100.00 99.94 99.94 99.60 98.04 9.5.14
Symptomatic 100.00 100.00 100.00 100.00 100.00 94.59
C054
Mild Phenotype 100.00 100.00 100.00 98.15 97.92 97.50
Symptomatic 15.fiS 11.06
6.84
5.93
5.72 5.16
%C03+/CD4- CD69
6.77
6.28
6.00
4.52 4.25
Mild Phenotype 19.09
1.89 1.72
2.53
1.95
Symptomatic
3.07
2.81
%C03+/CD4+ CD69 '
, Mild Phenotype
9.18
2.24
1.46
1.01
0.46 0.44
COI06

98.13 97.23 93.79 89.47 80.95 95.98 1.78
94.64 92.19 91.67 84.20 68.03 93.04 2.90
93.55 93.33 83.33 81.43 65.00 91.93 3.37
97.44 97.44 95.56 SS.OO 77.78 95.16 2.15
4.80 3.60 1.57 0.88 0.00 5.57 1.37
3.SS
1.52

2.27
1.00

O.'}7

1.86

1.16
0.80

0.49
0.00

5.11 1.54
1.66 0.28

0.42

0.38

0.33

0.30

0.00

1.47 0.79

5.4 DISCUSSION

Published literature indicates that

SeD patients that certain activation markers are

expressed during periods of vasoocclusive crisis. Leukocytes interact with sickle
erythrocytes and damaged endothelium layer through these activation markers and may
contribute to vasoocclusion [19]. Hence, it is important to accurately determine the
activation status and gene expression profile of the circulating cell populations in

seD

patients in order to realize and avert the onset of vasoocclusion. Interpretation of
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activation status will be affected by sample preparation technique without cell loss and
artifactual activation, significantly impacting the study.

Data was first scored by percentage of a nucleated cell population according to phenotype
marker in terms of total nucleated cells enriched by microfluidic lysis. Each population
was then analyzed by activation markers and the percentage of the population exhibiting
relative high activation was recorded. Markers for leukocytes and circulating endothelial
cells were obtained from literature as the most widely used for each population in terms
of phenotype and activation using flow cytometry [18, 29, 30]. Results comparing mild
phenotype and symptomatic SCD patients have shown on average that no statistical
difference exists based on percentage of nucleated cell populations and activation of these
populations between the two groups, as shown in Figures 12-17. Rather, the percentages
vary from among patients in each group, with coinciding upper and lower values,
depicted in Tables 5-6. Although a statistical exception arises with CD62L on CDI4+
Monocytes (Figure 14), activation of this marker still notably varies among mild
phenotype and symptomatic SCD patients (Table 6).

Significance of these results can be interpreted in terms of patient-to-patient variation.
Indeed, the percentage of circulating nucleated popUlations and their expression of
activation markers extremely fluctuates among the population, healthy controls and SCD
patients alike. Hence, due to such variability, one cannot definitively denote
vasoocclusive crisis by simple analysis of expression markers. Epigenetic effects
influenced by possibly mUltiple environmental factors may therefore be the primary
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candidate for onset of crisis. Although all patients have the same genetic defect, heritable
changes in the function of the gene occur without adjustments in the sequence
(epigenetics). Such changes may influence the variability in expression among SeD
patients. To render epigenetic effects on SeD one must first classify patients
appropriately.

Interrogating the immune status of an individual by staining for expression markers may
yet prove valuable. The extreme variability in the data infers that the manner by which
symptomatic seD patients are classified (mild phenotype or symptomatic) is too broad.
Perhaps this system could be improved by categorizing seD patients by age group and
specific symptoms (refer to Section 3.3) prior to placement in clinical studies. Until such
classification

IS

imposed studies claiming to identify risk factors continue to be

questionable. In conjunction with improving the classification of SeD patients, cell
expression studies may in fact reveal markers or cell populations that playa role for
particular groups of patients and possibly identify epigenetic effects. Such information
could lead to more personal and specific therapies for seD rather than prescription of
Common treatments.
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CHAPTER VI - CONCLUSIONS

6.1 CONCLUSIONS

A micro fluidic device and enrichment protocol of circulating nucleated cells has been
reported in this thesis. Superior performance in comparison to conventional enrichment
techniques has been confirmed. In particular, the microfluidic protocol prevents cell loss
and artifactual activation because of controlled exposure to harsh conditions. Further, the
capability of this technique to generate clinically valuable information was also
determined. The device, which allows for accurate analysis of the immune status of an
individual, was used to study the disease process in patients with sickle cell trait.

The first study in section 4 of the thesis compared healthy controls and mild phenotype
SCD patients. Results from the study indicated a non-specific increase in all circulating
nucleated cells, or no increase in any specific leukocyte population, and no activation in
mild phenotype SCD compared to healthy controls. From this data it was concluded that
mild phenotype patients are not in a state of chronic inflammation. Instead, these patients
are in a highly favorable state for an inflammatory response due to an increased baseline
leukocyte count, where a small stimulus could lead to activation of leukocytes and
vasoocclusive crisis. Ultimately, the study established the baseline leukocyte counts and
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activation status in mild phenotype SCD patients, data that can be used as a control for
future studies seeking to evaluate SCD patients in pain crisis.

The second study in section 5 compared mild phenotype and symptomatic SCD patients.
Results from this study indicated that there is extreme variability in clinical expression
among. individuals. Hence, it was concluded that one cannot definitively identify a single
population or marker that indicates a vasoocclusive crisis. Rather, the system used to
classify patients must first be revised in order to allow reports to discover risk factors in
SCD. Overall, the study provides valuable information on the immune status of
symptomatic SCD patients for evaluations seeking to measure severity of a vasoocclusive
crisis.

To sum up, a micro fluidic device has been developed and an enrichment protocol has
been established. Changes in fluid behavior due to scaling effects have been exploited
and manipulated. Processes have been achieved not feasible on the macro level. Indeed
developments in technological aspects of the microfluidics field continue to prove
invaluable.
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CHAPTER VII - FUTURE DIRECTIONS

7.1 FUTURE DIRECTIONS

Several different paths exist for potential future projects with the microfluidic lysis
device. In regards to Sickle cell disease (SCD) gene expression analyses can be carried
out in conjunction with the lysis device to determine genetic risk factors responsible for
the onset of a vasoocclusive crisis. These studies could provide further insight along with
flow cytometry in the development for more specialized treatment of SCD. Other
directions include investigating the role of circulating leukocytes in various diseases,
automating the device, and cell sorting for analysis of unknown nucleated populations.

7.1.1

DEVICE AUTOMATION

As the efficacy of the microfluidic device has been exemplified in terms of clinical use
and superiority to conventional techniques, the next step is complete device automation.
To gain acceptance in the clinical or research field the protocol must be simplified.
Hence, a platform can be developed eliminating user preparation steps and need for
external machinery, such as syringe pumps. In other words one has to simply inject the
blood sample and allow the apparatus to run. Below (Figure 18) is a representation of the
proposed automation. Figures 18a and 18b depict the microfluidic lysis and sorting
device in parallel with the fluids driven by a pressure source and a manifold with access
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holes to encase the microfluidic device. Means to rid of centrifugation after lysis to
separate out the nucleated cell populations via cell sorting is explained in the next
subsection.
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Figure 18: (a) Schematic representation of automated setup for leukocyte isolation.
(b) Solid Edge model of manifold for fluidic interconnects to microfluidic lysis device.

7.1.2

CELL SORTING

Cell sorting allows populations to be separated by certain characteristics, a process that
could eliminate centrifugation steps in the microfluidic lysis protocol. One distinguishing
feature among nucleated cell populations and red blood cell debris is size. A device has
been proposed in collaboration with Aman Russom, Center for Engineering in Medicine,
Massachusetts General Hospital, Harvard Medical School, that separates particles based
upon size utilizing Dean flow [31]. Particles experience transverse and longitudinal
forces in a curved surface. Forming a ratio of these values (transverse flow -;- longitudinal
flow) produces a dimensionless parameter, Dean's Number, that describes the outward
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force felt by a particle [3]. Figure 19 depicts an AutoCAD drawing of the cell sorting
device. Fluid enters from the center inlet via connecting tube from the lysis device.
Particles exit through one of 6 ports based on size and mix with 2X PBS (outermost port)
before exiting. Characterization of the sorter and combination with the lysis device would
lead to an automated system.

Figure 19. Schematic of proposed cell sorting device using Dean flow.

Another characteristic of nucleated cells is mass density. Based on this property cells
could be allowed to sediment within a microfluidic device. Employing theoretical values
for cell sedimentation as a guideline, an experimental design to sort nucleated cell
populations from red blood cell debris is possible, with flow rates determining time for
sedimentation. In combination with the lysis device an automated system could be
produced.

7.1.3

ANALYSIS OF UNKNOWN CELL POPULATIONS

Using the microfluidic lysis protocol to enrich nucleated cells, many interesting
populations were found

III

the scatter plots not typically seen with conventional
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techniques. Analysis of these unknown populations usmg flow cytometry or the
aforementioned methods of cell sorting may lead to discovery of cell populations rarely
seen in circulation. Ability to isolate and identify such populations may also lead to .'
diagnosis of disease.
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